Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Haolin Ni who wrote (860)	1/23/1998 11:12:00 AM
From: Ron	Read Replies (1) \| Respond to of 3579

Nothing wrong with trading GERN's ups and downs, but suggest you read this NYT article, then think about GERN as a long time buy and hold. It could be the mother of all buy and holds... : ) search.nytimes.com

To: Haolin Ni who wrote (860)	1/23/1998 2:06:00 PM
From: BulbaMan	Read Replies (2) \| Respond to of 3579

Geron may well have received substantial funds from Boehringer Mannheim in their recent telomerase diagnostic deal. The details of many biotech partnership deals are not made public because one or both parties consider such details business secrets. In the diagnostic deal, my guess is Boehringer Mannheim was the one desiring privacy. As I noted in a prior post, Geron CEO, Ron Eastman, has publicly declared the diagnostic deal was done on very favorable terms for Geron.